AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7524457
Drug: Topical aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical aprotinin (50 mL; 70 mg)
Trial: 3036335
Drug: New drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drugs and drug combinations for recurrent Wilms' tumor
Trial: 3036335
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for localized embryonal rhabdomyosarcoma
Trial: 3036335
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for tumors of the prostate, bladder neck, or trigone
Trial: 3036335
Drug: Platinum-containing combination
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-containing combination chemotherapy regimens for advanced yolk sac tumor
Trial: 3036335
Drug: New drug
RxNorm normalized name: varicella zoster immune globulin (Investigational New Drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drug combinations in locally advanced tumors
Trial: 3036335
Drug: Etoposide-containing combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide-containing combination chemotherapy regimens
Trial: 29358433
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + prescribed fluid intake
Trial: 29358433
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + usual fluid intake
Trial: 12434259
Drug: 200 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/70 kg oral caffeine t.i.d. (caffeine maintenance)
Trial: 15010695
Drug: Intravenous nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nicotine (1.0 and 2.0 mg/70 kg)
Trial: 15010695
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine (200 and 400 mg/70 kg)
Trial: 3513529
Drug: Guanfacine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (1 mg/day, adjustable to max 3 mg/day)
Trial: 28298187
Drug: internet-delivered transdiagnostic
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered transdiagnostic cognitive behavioural therapy (iCBT)
Trial: 26181090
Drug: Family planning
RxNorm normalized name: Lubricant Topical application Gel/Jelly [FAMILY PLANNING LIQUID LUBRICANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family planning services (counseling, prescription or procedure related to birth control)
Trial: 12804986
Drug: Calcitriol 3
RxNorm normalized name: CALCITRIOL 3MCG/GM OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 3 mug/g ointment
Trial: 12804986
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 mug/g ointment
Trial: 10989245
Drug: Tibolone therapy
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone therapy (group T)
Trial: 10989245
Drug: Continuous conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous conjugated estrogen (CE) 0.625 mg plus medroxyprogesterone acetate (MPA) 2.5 mg (group E)
Trial: 6533776
Drug: Tinidazole prophylaxis
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole prophylaxis with 8-h dosage interval (500 mg intravenous infusion)
Trial: 6533776
Drug: Tinidazole prophylaxis
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole prophylaxis with 12-h dosage interval (500 mg intravenous infusion)
Trial: 6533776
Drug: Tinidazole prophylaxis
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole prophylaxis (500 mg intravenous infusion)
Trial: 28483191
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (control group)
Trial: 25587312
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g magnesium sulfate in normal saline infused in 20 minutes on days one to three (case group)
Trial: 25587312
Drug: Standard medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medications and placebo (control group)
Trial: 25587312
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g magnesium sulfate in normal saline (case group)
Trial: 25587312
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (case group)
Trial: 22968127
Drug: Arthroscopic partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic partial meniscectomy combined with a standardized physical therapy program
Trial: 22968127
Drug: Standardized physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physical therapy program alone
Trial: 12170856
Drug: Two-implant overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant overdenture on ball attachments
Trial: 11158794
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (observed without therapy)
Trial: 29725986
Drug: Active analgesic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active analgesic treatment (paracetamol or buprenorphine transdermal system)
Trial: 16816307
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (n=21)
Trial: 16816307
Drug: Brief dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief dynamic therapy (n=23)
Trial: 12784590
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg per kg body weight, administered over 3 days)
Trial: 10791849
Drug: Chemotherapy (+)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (+) in TS-(+) group
Trial: 10791849
Drug: Chemotherapy (-)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (-) in TS-(+) group
Trial: 10791849
Drug: Chemotherapy (+)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (+) in TS-(‐) group
Trial: 10791849
Drug: Chemotherapy (-)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (-) in TS-(‐) group
Trial: 1495743
Drug: Calcitonin nasal
RxNorm normalized name: calcitonin nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin nasal spray (300 MRC units)
Trial: 30856378
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and fluoxetine (COMB)
Trial: 30856378
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) vs. Fluoxetine (FLX)
Trial: 30856378
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FLX) vs. Combination of CBT and fluoxetine (COMB)
Trial: 30856378
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) vs. Combination of CBT and fluoxetine (COMB)
Trial: 24515550
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist intervention involving medication reconciliation, patient education, and improved communication of the discharge medication plan.
Trial: 16791807
Drug: BMC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMC therapy
Trial: 9854660
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 50 mg/kg
Trial: 16077392
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 100 mg/kg
Trial: 9854660
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 150 mg/kg
Trial: 8568017
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with food (medium-fat breakfast)
Trial: 8568017
Drug: Atorvastatin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin without food (fasting)
Trial: 26466809
Drug: Standard intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intervention A: continuance of oral intake and regular mouth care
Trial: 26466809
Drug: Standard intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intervention B: continuance of oral intake, regular mouth care and clinically assisted hydration
Trial: 21385928
Drug: sulindac (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulindac (300 mg daily)
Trial: 21385928
Drug: etodolac (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etodolac (400 mg daily)
Trial: 18977478
Drug: Simvastatin 20mg
RxNorm normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20mg once daily for 2 months
Trial: 18977478
Drug: Pravastatin 40mg
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40mg once daily for 2 months
Trial: 9380241
Drug: Active-type vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-type vitamin D3 (VD) administered to Group 2 (19 patients; 10 males and 9 females)
Trial: 9380241
Drug: No active-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active-type vitamin D3 (VD) administered to Group 1 (19 patients; 15 males and 4 females)
Trial: 7700068
Drug: Antihypertension therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertension therapy
Trial: 29459361
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg
Trial: 23391676
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 or 120 mg daily
Trial: 7033016
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg daily
Trial: 11158556
Drug: Various interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various interventions in pregnancy/perinatal medicine
Trial: 11158556
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents for prevention of pre-eclampsia
Trial: 2525996
Drug: Aztreonam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis)
Trial: 2525996
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg BID)
Trial: 28753932
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng (3000 mg/day) for three months
Trial: 23979005
Drug: Behavioral weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral weight gain prevention intervention (medium-intensity) including tailored behavior change goals, weekly self-monitoring via interactive voice response, monthly counseling calls, tailored skills training materials, and a gym membership.
Trial: 21782874
Drug: rHPIV3cp45 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHPIV3cp45 vaccine (10^5 TCID50 dose)
Trial: 19035501
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1,000 mg of calcium and 400 IU of vitamin D)
Trial: 16798389
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and aspirin plus bivalirudin
Trial: 12672184
Drug: Ro 45‐2081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 45‐2081 (low dose 0.05 mg/kg, maximum 5 mg)
Trial: 12672184
Drug: Ro 45‐2081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 45‐2081 (mid-dose 0.2 mg/kg, maximum 20 mg)
Trial: 12672184
Drug: Ro 45‐2081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 45‐2081 (high dose 0.5 mg/kg, maximum 50 mg)
Trial: 8704438
Drug: Yangxueshengru Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxueshengru Oral Liquor (YXSR)
Trial: 2666884
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of 2 g cefotetan
Trial: 2666884
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose of 1 g intravenous cephazolin
Trial: 28724846
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg three times daily for nine months)
Trial: 28724846
Drug: Sibutramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (10 or 15 mg once daily for nine months)
Trial: 24300630
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential treatment
Trial: 24300630
Drug: 10-day conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day conventional treatment
Trial: 31982359
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg pregabalin
Trial: 21786524
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg midazolam (placebo)
Trial: 17924845
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II)
Trial: 17924845
Drug: Immediate curative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate curative therapy without CAB (Group I)
Trial: 15083959
Drug: Daily OL-HDF
RxNorm normalized name: limonen-10-ol, (+)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily OL-HDF (2 to 2.5 hours, six times per week)
Trial: 15083959
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly OL-HDF (4 to 5 hours) - Control group
Trial: 31045589
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg/d)
Trial: 24169302
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injection (3.5 mL of autologous platelets buffered with 8.4% sodium bicarbonate)
Trial: 24169302
Drug: Glucocorticoid (GC)
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (GC) injection (1 mL triamcinolone, 40 mg/mL + 2 mL lidocaine, 10 mg/mL)
Trial: 24169302
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (3 mL saline, 0.9%)
Trial: 17924889
Drug: Continuous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous remifentanil infusion
Trial: 16717305
Drug: Intermittent morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent morphine alone
Trial: 16935471
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 3% VC-IP cream for 3 weeks
Trial: 10598693
Drug: Combination (COSOPT)
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (COSOPT)
Trial: 29255098
Drug: Probiotic capsules
RxNorm normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsules (24 × 10^9 colony-forming units of lactobacilli and bifidobacteria)
Trial: 29255098
Drug: Sorbitol gum
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol gum (5 pieces daily)
Trial: 29255098
Drug: Xylitol gum
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol gum (15% xylitol; 5 pieces daily)
Trial: 23297867
Drug: Methylphenidate (Concerta®),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (Concerta®), up-titrated over 2 weeks to a maximum dose of 54 mg daily for 20 weeks, given under daily supervision.
Trial: 23297867
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered under the same conditions as methylphenidate.
Trial: 21894705
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCIA) with Sufentanil
Trial: 19850248
Drug: Reduced-dose reteplase
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose reteplase + abciximab
Trial: 17234657
Drug: High-selenium yeast
RxNorm normalized name: HIGH SELENIUM YEAST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-selenium yeast preparation (100 microg daily, n=99)
Trial: 15293890
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/day) and veralipride (100 mg/day) on alternate days (n = 17)
Trial: 15293890
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/day) and veralipride (100 mg/day) on alternate months (n = 12)
Trial: 9403933
Drug: Topical dinitrochlorobenzene
RxNorm normalized name: Dichlorobenzene
DrugBank: Dichlorobenzene (DB14046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dinitrochlorobenzene (DNCB) therapy
Trial: 9403933
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no DNCB therapy)
Trial: 7981429
Drug: MK-679 500
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-679 500 mg
Trial: 8389106
Drug: MK-679 125
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-679 125 mg
Trial: 3549028
Drug: Tubocurarine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine 0.05 mg X kg‐1
Trial: 31551217
Drug: Clopidogrel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel treatment (Control)
Trial: 28221247
Drug: eHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth intervention using the web-application young.constant-care.com (YCC) on a monthly basis and during flare-ups, with annual outpatient visits.
Trial: 16677182
Drug: Oral functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral functional training plus high-calorie and high-protein diet
Trial: 16677182
Drug: High-calorie and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie and high-protein diet (supplement group)
Trial: 15290410
Drug: Epinephrine group
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine group (n = 10) received 14 mg of tetracaine and 0.2 mg of epinephrine
Trial: 15290410
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 10) received 14 mg of tetracaine
Trial: 9666867
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (0.25 IU/kg/week)
Trial: 10741688
Drug: Placebo (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (first 6 months) then switched to GH therapy
Trial: 2803050
Drug: Piracetam 8
RxNorm normalized name: piracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 8 g
Trial: 26180352
Drug: Flexion-distraction manipulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexion-distraction manipulation therapy combined with conservative physical therapy
Trial: 26180352
Drug: Conservative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative physical therapy
Trial: 10754625
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream and plastic occlusive dressing
Trial: 10754625
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream and plastic occlusive dressing
Trial: 10754625
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream and plastic occlusive dressing for 60 min
Trial: 8970892
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral phosphate dose (1500 mg in water)